MA51612A - Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant - Google Patents
Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiantInfo
- Publication number
- MA51612A MA51612A MA051612A MA51612A MA51612A MA 51612 A MA51612 A MA 51612A MA 051612 A MA051612 A MA 051612A MA 51612 A MA51612 A MA 51612A MA 51612 A MA51612 A MA 51612A
- Authority
- MA
- Morocco
- Prior art keywords
- cyclodextrin
- beta
- gelling agent
- bilastin
- ophthalmic compositions
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 239000001116 FEMA 4028 Substances 0.000 title abstract 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title abstract 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 title abstract 2
- 229960004853 betadex Drugs 0.000 title abstract 2
- 239000003349 gelling agent Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 abstract 2
- 229960004314 bilastine Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 abstract 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition pharmaceutique ophtalmique aqueuse comprenant : a) au moins 0,4 % p/v de bilastine de formule (i) ou d'un sel ou d'un solvate pharmaceutiquement acceptable correspondant, le sel ou le solvate correspondant de bilastine étant complètement dissous dans la composition pharmaceutique ; b) au moins une bêta-cyclodextrine ; et c) au moins un agent gélifiant soluble dans l'eau pharmaceutiquement acceptable ; et le ph étant compris entre 4 et 9, et son utilisation dans le traitement et/ou la prévention d'états médiés par le récepteur de l'histamine h1, tels que des troubles ou des maladies allergiques. L'invention concerne le traitement et/ou la prévention de conjonctivite allergique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382021 | 2018-01-18 | ||
| PCT/EP2019/050433 WO2019141563A1 (fr) | 2018-01-18 | 2019-01-09 | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51612A true MA51612A (fr) | 2020-11-25 |
| MA51612B1 MA51612B1 (fr) | 2021-06-30 |
Family
ID=61017875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51612A MA51612B1 (fr) | 2018-01-18 | 2019-01-09 | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20210128544A1 (fr) |
| EP (2) | EP3740191B1 (fr) |
| JP (1) | JP7309729B2 (fr) |
| KR (1) | KR102695627B1 (fr) |
| CN (1) | CN111727035B (fr) |
| AR (1) | AR114216A1 (fr) |
| AU (1) | AU2019209214B2 (fr) |
| BR (1) | BR112020014265A2 (fr) |
| CA (1) | CA3088740A1 (fr) |
| CL (1) | CL2020001895A1 (fr) |
| CO (1) | CO2020009992A2 (fr) |
| CY (1) | CY1124270T1 (fr) |
| DK (1) | DK3740191T3 (fr) |
| EA (1) | EA202091725A1 (fr) |
| ES (1) | ES2878107T3 (fr) |
| HR (1) | HRP20211037T1 (fr) |
| HU (1) | HUE054594T2 (fr) |
| LT (1) | LT3740191T (fr) |
| MA (1) | MA51612B1 (fr) |
| MX (1) | MX2020007692A (fr) |
| PL (1) | PL3740191T3 (fr) |
| PT (1) | PT3740191T (fr) |
| SA (1) | SA520412443B1 (fr) |
| SI (1) | SI3740191T1 (fr) |
| TW (1) | TWI833727B (fr) |
| UY (1) | UY38055A (fr) |
| WO (1) | WO2019141563A1 (fr) |
| ZA (1) | ZA202005077B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024009978A (es) | 2022-02-17 | 2024-08-26 | Faes Farma Sa | Composicion de bilastina para administracion parenteral una vez al dia. |
| CN116211795B (zh) * | 2022-12-26 | 2025-09-26 | 深圳市贝美药业有限公司 | 一种比拉斯汀口服液体制剂及其制备方法 |
| CN115970066B (zh) * | 2022-12-29 | 2024-09-27 | 成都爱睿康乐医疗器械有限公司 | 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用 |
| WO2024224326A1 (fr) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Formulations parentérales liquides de bilastine |
| WO2024224308A1 (fr) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Formulations parentérales liquides de bilastine exemptes de cyclodextrines |
| WO2024256956A1 (fr) * | 2023-06-13 | 2024-12-19 | Leiutis Pharmaceuticals Llp | Formulations stables de bilastine pour utilisation nasale et ophtalmique |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| ES2048109B1 (es) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| JP3527256B2 (ja) | 1992-12-09 | 2004-05-17 | ロート製薬株式会社 | 抗アレルギー点眼剤 |
| TW401300B (en) | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| BRPI0215703B8 (pt) | 2002-04-19 | 2021-05-25 | Faes Farma Sa | polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1 |
| US20050239745A1 (en) * | 2004-03-03 | 2005-10-27 | Ophthalmic Research Associates, Inc. | Novel topical ophthalmic formulations |
| US7247623B2 (en) | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| US20070082870A1 (en) | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| NZ571690A (en) * | 2006-03-31 | 2011-09-30 | Vistakon Pharmaceuticals Llc | Ocular allergy treatments using alcaftadine |
| UA94938C2 (ru) * | 2006-03-31 | 2011-06-25 | ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи | Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты) |
| CN101795565A (zh) | 2007-06-28 | 2010-08-04 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
| WO2010107525A1 (fr) * | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Formulations ophtalmiques de kétotifène et procédés d'utilisation |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| CN103110575B (zh) * | 2013-03-07 | 2014-11-05 | 宁夏康亚药业有限公司 | 一种美洛昔康滴眼液及其制备方法和应用 |
| WO2014150899A1 (fr) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Formulations ophtalmiques topiques pour traiter la migraine |
| CN103784462A (zh) * | 2014-02-25 | 2014-05-14 | 宋俊智 | 包含比拉斯汀及甾族化合物的药物制剂 |
| EP3040334A1 (fr) | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | Nouveaux dérivés de benzimidazole en tant qu'agents antihistaminiques |
-
2019
- 2019-01-09 DK DK19701154.7T patent/DK3740191T3/da active
- 2019-01-09 CN CN201980009293.0A patent/CN111727035B/zh active Active
- 2019-01-09 WO PCT/EP2019/050433 patent/WO2019141563A1/fr not_active Ceased
- 2019-01-09 US US16/963,219 patent/US20210128544A1/en not_active Abandoned
- 2019-01-09 EP EP19701154.7A patent/EP3740191B1/fr active Active
- 2019-01-09 EA EA202091725A patent/EA202091725A1/ru unknown
- 2019-01-09 EP EP21169956.6A patent/EP3915539A1/fr not_active Withdrawn
- 2019-01-09 MX MX2020007692A patent/MX2020007692A/es unknown
- 2019-01-09 MA MA51612A patent/MA51612B1/fr unknown
- 2019-01-09 PT PT197011547T patent/PT3740191T/pt unknown
- 2019-01-09 BR BR112020014265-4A patent/BR112020014265A2/pt active Search and Examination
- 2019-01-09 HR HRP20211037TT patent/HRP20211037T1/hr unknown
- 2019-01-09 LT LTEP19701154.7T patent/LT3740191T/lt unknown
- 2019-01-09 SI SI201930076T patent/SI3740191T1/sl unknown
- 2019-01-09 AU AU2019209214A patent/AU2019209214B2/en active Active
- 2019-01-09 JP JP2020539288A patent/JP7309729B2/ja active Active
- 2019-01-09 ES ES19701154T patent/ES2878107T3/es active Active
- 2019-01-09 KR KR1020207023573A patent/KR102695627B1/ko active Active
- 2019-01-09 CA CA3088740A patent/CA3088740A1/fr not_active Abandoned
- 2019-01-09 PL PL19701154T patent/PL3740191T3/pl unknown
- 2019-01-09 HU HUE19701154A patent/HUE054594T2/hu unknown
- 2019-01-17 AR ARP190100094A patent/AR114216A1/es not_active Application Discontinuation
- 2019-01-17 TW TW108101861A patent/TWI833727B/zh active
- 2019-01-18 UY UY38055A patent/UY38055A/es not_active Application Discontinuation
-
2020
- 2020-07-15 SA SA520412443A patent/SA520412443B1/ar unknown
- 2020-07-17 CL CL2020001895A patent/CL2020001895A1/es unknown
- 2020-08-13 CO CONC2020/0009992A patent/CO2020009992A2/es unknown
- 2020-08-17 ZA ZA2020/05077A patent/ZA202005077B/en unknown
-
2021
- 2021-06-25 CY CY20211100569T patent/CY1124270T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51612A (fr) | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant | |
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
| TNSN98082A1 (fr) | DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A. | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA56674B1 (fr) | Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci | |
| MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA49673B1 (fr) | Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer | |
| MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
| MA54870B1 (fr) | Pyrazolopyridines et triazolopyridines utilisées en tant qu'inhibiteurs a2a/a2b | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| MA53010B1 (fr) | Formulations d'un inhibiteur de axl/mer | |
| MA47082B1 (fr) | Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1 | |
| WO2018224736A3 (fr) | Dérivés stéroïdiens thérapeutiquement actifs | |
| MA28237A1 (fr) | Composition pharmaceutique de vinflunine destinee a une administration parenterale, procede de preparation et utilisation | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| MA62917A1 (fr) | Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens | |
| EA202090965A1 (ru) | Водные композиции биластина | |
| NO940064L (no) | Öyepreparat på polyakrylsyrebasis | |
| EP4230226A4 (fr) | Composition pour le traitement de maladies rétiniennes ou choroïdiennes, contenant un inhibiteur d'acta2 comme principe actif |